A citation-based method for searching scientific literature

Daniel B Maselli, Michael Camilleri. Adv Exp Med Biol 2021
Times Cited: 8







List of co-cited articles
14 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.
Julie B Hjerpsted, Anne Flint, Ashley Brooks, Mads B Axelsen, Trine Kvist, John Blundell. Diabetes Obes Metab 2018
46
37

Gastric emptying and glycaemia in health and diabetes mellitus.
Liza K Phillips, Adam M Deane, Karen L Jones, Chris K Rayner, Michael Horowitz. Nat Rev Endocrinol 2015
119
37

Paracetamol as a Post Prandial Marker for Gastric Emptying, A Food-Drug Interaction on Absorption.
R Bartholomé, B Salden, M F Vrolijk, F J Troost, A Masclee, A Bast, G R Haenen. PLoS One 2015
11
37

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Helle Linnebjerg, Soomin Park, Prajakti A Kothare, Michael E Trautmann, Kenneth Mace, Mark Fineman, Ian Wilding, Michael Nauck, Michael Horowitz. Regul Pept 2008
169
37

Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.
Karen L Jones, Lian Q Huynh, Seva Hatzinikolas, Rachael S Rigda, Liza K Phillips, Hung T Pham, Chinmay S Marathe, Tongzhi Wu, Charles H Malbert, Julie E Stevens,[...]. Diabetes Obes Metab 2020
12
37

Gastric Emptying in Patients With Well-Controlled Type 2 Diabetes Compared With Young and Older Control Subjects Without Diabetes.
Linda E Watson, Cong Xie, Xuyi Wang, Ziyi Li, Liza K Phillips, Zilin Sun, Karen L Jones, Michael Horowitz, Christopher K Rayner, Tongzhi Wu. J Clin Endocrinol Metab 2019
18
25

Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Houssam Halawi, Disha Khemani, Deborah Eckert, Jessica O'Neill, Hoda Kadouh, Karen Grothe, Matthew M Clark, Duane D Burton, Adrian Vella, Andres Acosta,[...]. Lancet Gastroenterol Hepatol 2017
61
25

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
Martin Lorenz, Claudia Pfeiffer, Axel Steinsträsser, Reinhard H A Becker, Hartmut Rütten, Peter Ruus, Michael Horowitz. Regul Pept 2013
102
25

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Juris J Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A Menge, Thomas Forst, Christoph Kapitza. Diabetes Care 2015
160
25

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon, Alicja Wizert, Dorthe Skovgaard. Diabetes Obes Metab 2021
6
33


Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
John Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Trine Kvist, Julie B Hjerpsted. Diabetes Obes Metab 2017
95
25

Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying.
Michael Horowitz, Christopher K Rayner, Chinmay S Marathe, Tongzhi Wu, Karen L Jones. Diabetes Obes Metab 2020
6
33

Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
Kirsten Dahl, Ashley Brooks, Firas Almazedi, Søren Tetens Hoff, Cristina Boschini, Tine A Baekdal. Diabetes Obes Metab 2021
5
40

Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
J Ma, A N Pilichiewicz, C Feinle-Bisset, J M Wishart, K L Jones, M Horowitz, C K Rayner. Diabet Med 2012
56
12

Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus.
M Horowitz, A F Maddox, J M Wishart, P E Harding, B E Chatterton, D J Shearman. Eur J Nucl Med 1991
268
12

Validation of 13C-acetic acid breath test by measuring effects of loperamide, morphine, mosapride, and itopride on gastric emptying in mice.
Kenjiro Matsumoto, Hiroshi Kimura, Kimihito Tashima, Masayuki Uchida, Syunji Horie. Biol Pharm Bull 2008
21
12

Hypoglycaemia and gastric emptying.
Chinmay S Marathe, Jessica A Marathe, Christopher K Rayner, Palash Kar, Karen L Jones, Michael Horowitz. Diabetes Obes Metab 2019
9
12

Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
Christian S Frandsen, Thomas F Dejgaard, Henrik U Andersen, Jens J Holst, Bolette Hartmann, Birger Thorsteinsson, Sten Madsbad. Diabetes Obes Metab 2017
14
12

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Michael A Nauck, Guido Kemmeries, Jens J Holst, Juris J Meier. Diabetes 2011
206
12

Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.
Mahesh M Umapathysivam, Michael Y Lee, Karen L Jones, Christopher E Annink, Caroline E Cousins, Laurence G Trahair, Chris K Rayner, Marianne J Chapman, Michael A Nauck, Michael Horowitz,[...]. Diabetes 2014
77
12

Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders.
Christopher K Rayner, Karen L Jones, Tongzhi Wu, Michael Horowitz. Diabetes Obes Metab 2017
8
12

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
717
12

Incretins in obesity and diabetes.
Chee W Chia, Josephine M Egan. Ann N Y Acad Sci 2020
19
12


Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD.
Marta Seghieri, Alexander S Christensen, Andreas Andersen, Anna Solini, Filip K Knop, Tina Vilsbøll. Front Endocrinol (Lausanne) 2018
27
12

Give the receptor a brake: slowing gastric emptying by GLP-1.
Jenny Tong, David D'Alessio. Diabetes 2014
26
12





Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
167
12

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
200
12

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Ildiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, Harish Kumar, Nanna L Lausvig, Carel W le Roux, Desirée Thielke, Adie Viljoen, Rory J McCrimmon. Lancet Diabetes Endocrinol 2019
57
12

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
697
12

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Robert F Kushner, Salvatore Calanna, Melanie Davies, Dror Dicker, W Timothy Garvey, Bryan Goldman, Ildiko Lingvay, Mette Thomsen, Thomas A Wadden, Sean Wharton,[...]. Obesity (Silver Spring) 2020
31
12

The effect of obesity on acetaminophen pharmacokinetics in man.
W H Lee, W G Kramer, G E Granville. J Clin Pharmacol 1981
31
12


Progress and challenges in anti-obesity pharmacotherapy.
Daniel H Bessesen, Luc F Van Gaal. Lancet Diabetes Endocrinol 2018
65
12

Semaglutide lowers body weight in rodents via distributed neural pathways.
Sanaz Gabery, Casper G Salinas, Sarah J Paulsen, Jonas Ahnfelt-Rønne, Tomas Alanentalo, Arian F Baquero, Stephen T Buckley, Erzsébet Farkas, Csaba Fekete, Klaus S Frederiksen,[...]. JCI Insight 2020
42
12

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
W Timothy Garvey, Jeffrey I Mechanick, Elise M Brett, Alan J Garber, Daniel L Hurley, Ania M Jastreboff, Karl Nadolsky, Rachel Pessah-Pollack, Raymond Plodkowski. Endocr Pract 2016
368
12

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
12

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain. Lancet Diabetes Endocrinol 2017
163
12


The Discovery and Development of Liraglutide and Semaglutide.
Lotte Bjerre Knudsen, Jesper Lau. Front Endocrinol (Lausanne) 2019
91
12


Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Helena W Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood. J Clin Endocrinol Metab 2018
84
12


Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
164
12

Obesity, sex, and acetaminophen disposition.
D R Abernethy, M Divoll, D J Greenblatt, B Ameer. Clin Pharmacol Ther 1982
98
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.